BIND Biosciences, Inc.BIND Biosciences, Inc. (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles to produce best in class drugs. The company was founded by two pioneers in the field: Dr. Robert Langer of MIT and Dr. Omid Farokhzad of Harvard Medical School. about Bind BiosciencesJoin Our Growing TeamBIND's collaborative culture provides a unique opportunity for talented and creative individuals to make a significant contribution in developing breakthrough targeted therapeutics. We are rapidly expanding to build a great company. view opportunities |
Our TechnologyBIND proprietary Medicinal Nanoengineering™ platform enables the design, engineering and manufacturing of targeted nanoparticle therapeutics with unprecedented control over drug PK; biodistribution; cell- or tissue-specific targeting; and drug exposure kinetics. Medicinal Nanoengineering complements medicinal chemistry to enable predictable and rapid development of breakthrough products with superior efficacy and safety profiles. Our initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010.
|
News at BIND Biosciences
|
| Copyright ©2010 | BIND Biosciences, Inc | home | contact us | privacy | site map | Website Design by Garfield Group |
| BIND Biosciences, Inc. | 64 Sidney Street | Cambridge, MA 02139 | P: 617-491-3400 | ||